VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-Of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

PLoS ONE - United States
doi 10.1371/journal.pone.0047485
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Strategies to Improve Efficacy and Safety of a Novel Class of Antiviral Hyper-Activation-Limiting Therapeutic Agents: The VS411 Model HIV/AIDS

British Journal of Pharmacology
Pharmacology
2010English

Excision of HIV-1 DNA by Gene Editing: A Proof-Of-Concept in Vivo Study

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2016English

Protective HLA Alleles Are Associated With Reduced LPS Levels in Acute HIV Infection With Implications for Immune Activation and Pathogenesis

PLoS Pathogens
ImmunologyMolecular BiologyVirologyMicrobiologyParasitologyGenetics
2019English

Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2015English

Immune Activation and HIV

Current Opinion in HIV and AIDS
VirologyOncologyInfectious DiseasesImmunologyHematology
2016English

Antiviral Therapeutics for Chikungunya Virus

Expert Opinion on Therapeutic Patents
MedicineDrug DiscoveryPharmacology
2020English

Immune Activation and HIV Persistence

Current Opinion in HIV and AIDS
VirologyOncologyInfectious DiseasesImmunologyHematology
2013English

Α1Proteinase Inhibitor Regulates CD4+ Lymphocyte Levels and Is Rate Limiting in HIV-1 Disease

PLoS ONE
Multidisciplinary
2012English

Ideal Protein Concept in Broiler Starter Phase (0-28 Days) Using Low-Protein Diets Supplemented With the Most Limiting Essential Amino Acids

Journal of Experimental Agriculture International
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy